Gene therapy with RNA interference (RNAi) as an alternative for the treatment of various diseases has been increasingly studied and understood by many research groups around the world. Interference with RNAi is a process closely related to the gene expression; it can be used not only for functional genomics research but also as a valuable tool for the treatment of diseases occurring mutation or overexpression gene. Several studies have shown promising results with the use of RNAi for treating skin diseases involving overexpression or deregulation of genes. However, the challenge is in the development of a safe and effective delivery system that can enable the use of siRNAs for treatment of diseases. Vitiligo is an autoimmune disease of the skin characterized by progressive loss of cells responsible for the synthesis of the pigment melanin (melanocytes), resulting in melanocyte destruction by autoantibodies from the patient. A therapeutic target for gene therapy silencing can be the TRP-1 (Tyrosinase-related protein 1) since it is expressed in the membrane of melanocytes as a target for destruction, a condition shown in vitiligo. In this aspect, this project aims to evaluate in vivo and in vitro nanodispersões liquid-crystalline with siRNAi-TRP-1 specific as a carrier for the topical treatment of vitiligo.
News published in Agência FAPESP Newsletter about the scholarship: